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Clinical use of 2-deoxystreptamine aminoglycoside antibiotics, which target the bacterial
ribosome, is compromised by adverse effects related to limited drug selectivity. Here we
present a series of 40,60-O-acetal and 40-O-ether modiﬁcations on glucopyranosyl ring I of
aminoglycosides. Chemical modiﬁcations were guided by measuring interactions between the
compounds synthesized and ribosomes harbouring single point mutations in the drug-binding
site, resulting in aminoglycosides that interact poorly with the drug-binding pocket of
eukaryotic mitochondrial or cytosolic ribosomes. Yet, these compounds largely retain their
inhibitory activity for bacterial ribosomes and show antibacterial activity. Our data indicate
that 40-O-substituted aminoglycosides possess increased selectivity towards bacterial
ribosomes and little activity for any of the human drug-binding pockets.
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S
electivity is of particular concern for ribosomal antibiotics1,2
as the ribosome is present in all three domains of life and is
a relatively conserved structure. Among this class,
aminoglycosides are listed by the WHO as critically important
antimicrobials for human therapy3. Their high efﬁcacy, broad-
spectrum antibacterial potency and lack of drug-related allergy
are well-known features and make aminoglycosides a common
choice for the treatment of serious infections including
multidrug-resistant tuberculosis4. A major drawback of amino-
glycosides relates to their adverse effects. Aminoglycoside-
induced ototoxicity, that is, the compounds’ ability to cause
irreversible hearing loss due to destruction of inner ear sensory
hair cells5, occurs in a sporadic, dose-dependent manner. In
addition, inherited forms of hypersensitivity to aminoglycoside
ototoxicity exist, which are linked to point mutations in
mitochondrial rRNA, such as A1555G and C1494U6,7. Recent
evidence converges on mitochondrial function as a key element in
aminoglycoside-induced ototoxicity, as experimental evidence
was provided for both aminoglycoside-induced dysfunction of the
mitochondrial ribosome and A1555G/C1494U-linked mito-
chondrial hypersusceptibility to aminoglycoside antibiotics8,9.
These ﬁndings suggest that aminoglycoside ototoxicity is directly
related to the drugs’ mechanism of action on the eukaryotic
ribosome.
The 2-deoxystreptamine aminoglycoside antibiotics bind to
helix 44 (h44) of 16S rRNA, which is part of the decoding site of
the bacterial 30S ribosomal subunit10,11, thereby decreasing
translational ﬁdelity and inhibiting translocation12–15. The
interaction core formed by rings I and II is mainly responsible
for drug binding. Ring I intercalates into the internal loop formed
by A1408, A1492, A1493 and the base pair C1409–G1491. Here
ring I becomes properly positioned by stacking interaction with
G1491 and the formation of hydrogen bonds with A1408 (Fig. 1).
Despite variations in chemical composition, ring I always binds in
the same orientation and forms a pseudo base-pair interaction
with the Watson–Crick edge of adenine 1408. The ring oxygen of
ring I accepts a hydrogen bond from the N6 of adenine, and the
amino- or hydroxyl-group at position 60 donates a hydrogen
bond to the N1 of adenine10,11. Additional hydrogen bonds link
the hydroxyl groups at positions 30 and 40 of ring I to the
phosphate groups of the two bulged adenine bases 1492 and 1493,
further stabilizing the position of ring I.
The use of 2-deoxystreptamine aminoglycosides as antimicro-
bial agents builds upon the compounds’ preferential activity for
the prokaryotic versus the eukaryotic ribosome1,2. At the
structural level, the selectivity of these compounds rests upon
two residues in the drug-binding pocket—residues 1408 and 1491
(refs 16–19). Residue 1408 is an adenine in bacterial and
mitochondrial ribosomes as compared with a guanine in cytosolic
ribosomes. Residue 1491 is a guanine in bacterial ribosomes, but a
cytosine in mitochondrial and an adenine in cytosolic ribosomes.
Both these changes disrupt the bacterial C1409–G1491 base-pair
interaction (see Supplementary Fig. 1 for a comparison of
bacterial and eukaryotic drug-binding pockets). A guanine at
residue 1408 mainly affects 2-deoxystreptamines with a 60NH2 as
it would preclude the proper insertion of a corresponding ring I
into the binding pocket, that is, the 60 ammonium group cannot
accept hydrogen bonds from the Watson–Crick sites of the
guanine residue, and additionally its positive charge would create
repulsion against the N1 and N2 amino groups20. In contrast, 2-
deoxystreptamines with a 60OH group are less affected by a
1408G as the 60 hydroxyl group could still become an acceptor of
a hydrogen bond from N1 or N2 (ref. 20; Fig. 1). A C1409–C1491
opposition mainly affects 2-deoxystreptamines with a 60OH but
much less so compounds with a 60NH2. Possibly, the 60OH–N1
A1408 interaction is less stable as compared with the 60NH2–N1
A1408 interaction, making 60OH 2-deoxystreptamines
highly dependent on proper stacking interaction with residue
1491 (refs 21,22).
Here we address the question of whether the speciﬁcity of the
2-deoxystreptamine aminoglycosides can be modiﬁed to increase
selectivity at the drug-target level in spite of the constraints
imposed by the high conservation of the drug-binding pocket. We
focus on ring I, as it interacts with phylogenetically variable 16S
rRNA residues 1408 and 1491. As we expected, structural
modiﬁcations on ring I affect drug selectivity. In addition, our
results reveal the unanticipated ﬁnding that well-known synthetic
intermediates can show promising biological properties.
Results
Synthesis of compounds and assessment of speciﬁcity. Par-
omomycin and neomycin are closely related 4,5-disubstituted
aminoglycosides, their structure differing by the ring I 60 sub-
stituent (60OH versus 60NH2, see Fig. 1c,d). Ring I of par-
omomycin was modiﬁed by substitutions of the 40 hydroxyl
position. We ﬁrst synthesized 40,60-O-acetals, starting with ben-
zylidene derivatives (Fig. 1e). The 40,60-O-benzylidene acetal 1
was synthesized and tested for growth inhibition activity (mini-
mal inhibitory concentration, MIC) of bacterial cells using wild
type and recombinant strains of Mycobacterium smegmatis with
single point mutations in the drug-binding pocket. The point
mutations were chosen to reﬂect the phylogenetically variable 16S
rRNA residues, namely positions 1408 (A bacterial/mitochon-
drial, G cytosolic) and 1491 (G bacterial, A cytosolic, C mito-
chondrial). We subsequently synthesized acetals 2–36 (for a
complete list of chemical structures synthesized see
Supplementary Fig. 2) to investigate structure–activity relations
(SAR) and compared their growth inhibition activity with those
of neomycin and paromomycin. As previously noted21, the
interaction of neomycin and paromomycin with the A site shows
varying degrees of speciﬁcity for A1408 and G1491. Thus, the
MIC activities (Table 1) demonstrate that interaction of the 60
amino neomycin is dependent on an adenine at residue 1408
(MIC for A1408 is 0.8 mM, MIC for G1408 is 4720mM),
while mutational alterations of G1491 have less of an effect (MIC
G1491 0.8 mM versus MIC C1491 27 mM). In comparison,
interaction of the 60 hydroxyl paromomycin with the ribosome
is less affected by a G1408 alteration (MIC A1408 1.6 mM versus
MIC G1408 102 mM) as compared with mutational alteration of
residue G1491 (MIC G1491 1.6 mM versus MIC C1491
4720 mM). Surprisingly, the interaction of the 40,60-O-acetals
with the A site was observed to be largely dependent on both
rRNA residues 1408 and 1491. Thus, high MIC values are
associated with each single nucleotide alteration affecting rRNA
residue A1408 or G1491 (MIC G1408 Z720mM, MIC C/A1491
Z720mM). MIC activities for selected acetals 1–3, 9 and 30 are
summarized in Table 1.
SAR studies based on430 acetals (see Supplementary Table 1
for a summary of MIC activities) revealed that the nature,
position and number of substituents at the equatorial hydro-
phobic residue at C(2) of the acetal 1,3-dioxane ring have a
modest effect on compound activity in general, for example,
replacement of the phenyl group in 1 by a 3- or 4-chlorophenyl
substituent (10, 2), a 4-ﬂuorophenyl substituent (6), a 3,5-
dichlorophenyl analogue (16), a 3- or 4-methoxyphenyl analogue
(11, 3), a 2,5-dimethoxyphenyl analogue (18), a 4-dimethylami-
nophenyl (4), a 3- or 4-hydroxyphenyl (12, 5), a 4-triﬂuor-
omethylphenyl (9), a 2-, 3- or 4-nitrophenyl analogue (15, 13,
and 7) all have relatively little effect. Together with the lower
activity of the cyclohexyl analogue 25 of 1 this suggests that
both hydrophobic and stacking interactions are relevant to the
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drug–ribosome interaction. This interpretation is in agreement
with the activities of 23 and 24, where the phenyl substituent has
been replaced by an electron-rich 2-furyl or 2-thiophenyl ring,
and with the activities of 26 and 27, possessing larger aromatic
moieties. Introducing a linker between the phenyl ring and C(2)
of the 1,3-dioxane ring had a marked effect on the properties of
the acetals: a two-carbon chain between the aromatic moiety and
C(2) of the 1,3-dioxane ring being optimal (1, 29–34). Disruption
of ring I of the benzylidene acetals abolishes activity (35 and 36
versus 1).
We next synthesized the C(40)O-substituted ethers 37 and
39–42, the linear acetal 43 and the C(60)O-substituted ether 38.
The MIC data (Table 2) demonstrate a similar selectivity proﬁle
for the C(40)O-substituted ethers 37 and 39–42 as for the
corresponding 40,60-O-acetal analogues 1–3, 9 and 30, respec-
tively. The acetal 1 and the C(40)-O-benzyl ether 37 show
signiﬁcantly higher antibacterial activity than the corresponding
C(60)-O-benzyl ether 38, and the linear acetal 43 is noticeably less
active than the corresponding cyclic acetal 30 (see summarized
MIC data in Supplementary Table 1). Altogether, this indicates
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Figure 1 | Interaction of ring I with residues in the A site loop of 16S rRNA. (a) Secondary structure of the aminoglycoside-binding pocket in helix 44 of
16S rRNA. Key polymorphic residues determining the selectivity of aminoglycosides are residues 1408 and 1491, highlighted in bold green. (b) Overview
of paromomycin bound to the bacterial A site. Detailed view of the 60OH paromomycin ring-I stacking interaction with G1491 and hydrogen bonding
with A1408 and A1493 (ref. 10). Hydrogen bonds between aminoglycoside ring I and A1408 are shown as red dotted lines, as is hydrogen bonding between
40OH and O2P of A1493. (c) Ring I interaction with A1408. Left paromomycin (Pm), right neomycin (Neo). Hydrogen bond interaction between the
60-subsituent (60OH, 60NH2) and the N1 of A1408 is indicated by a red dotted line, as is hydrogen bond interaction between O50 and N6 of A1408. (d) Ring I
interaction with G1408 (model)20. Left paromomycin, right neomycin. Possible hydrogen bond interactions are indicated by red dotted lines. The positive
charge of neomycin’s 60-ammonium group would create repulsion against the N1 and N2 amino groups of G1408, indicated by red arrows. (e) General
chemical structure of 40 ,60-O-acetals and 40-O-ethers in comparison to paromomycin, the 60 and 40 positions that were target for substitution are indicated.
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that proper orientation and location of the aromatic residue
rather than just hydrophobic effects are relevant for selectivity.
Drug–target interaction in cell-free translation assays. To study
drug–target interaction and the contribution of the polymorphic
residues 1408 and 1491 to drug binding more directly, we
assessed compound activity in cell-free ribosomal translation
assays for selected pairs of 40,60-O-acetals and corresponding 40-
O-ethers, that is, compounds 1, 2, 30, 37, 39 and 42. Compound
activity in the in vitro translation assay is deﬁned as the drug
concentration that inhibits the in vitro translation reaction by
50% (inhibitory concentration, IC50). Corroborating the MIC
data, the ribosomal activity of the 40,60-O-acetals and 40-O-ethers
was found to be highly dependent on both speciﬁc nucleobases
present at 16S rRNA positions 1408 and 1491, with little differ-
ence between corresponding acetals and ethers (Table 3). To
address the question of how these compounds affect the eukar-
yotic A site we assessed drug susceptibility of recombinant
bacterial hybrid ribosomes. The hybrid ribosomes were engi-
neered to carry the cytoplasmic A site, the mitochondrial wild-
type A site or the mitochondrial mutant deafness A site (A1555G,
C1494U)8,9,18. Neomycin and paromomycin each showed a
characteristic pattern of interaction with the eukaryotic drug-
binding pockets. In addition, both aminoglycosides interact
preferentially with the mitochondrial deafness A1555G, C1494U
mutant A site (Table 4). In contrast, the series of 40,60-O-acetals
and 40-O-ethers did not show a preferential activity for any of the
eukaryotic drug-binding pockets—these compounds are poor
inhibitors of mitochondrial, mitochondrial mutant deafness and
cytosolic hybrid ribosomes.
We compared the target speciﬁcity and drug–target interaction
of the present series of compounds with that of paromomycin,
neomycin, gentamicin, tobramycin, amikacin and kanamycin.
Aminoglycoside activity against 1491C and 1491A mutant
bacterial ribosomes correlates well (R2¼ 0.97), yet no such
correlation exists between the activity against 1491C and 1408G
mutant ribosomes (Supplementary Fig. 3). Compared with
Table 2 | Minimal inhibitory concentrations (MIC, lM) of C(40)-O-ethers.
Bacterial A site 
WT 5.6 2.8 11 11 5.6 
1491C >720 ≥720 ≥720 
1491A ≥720 ≥720 
1408G >720 
37 39 40 41 42
≥720 >720 
≥720 >720 >720 
≥720  >720 >680 ≥720 
Table 3 | Compound interaction with polymorphic residues in the drug-binding pocket (IC50, lM).
Bacterial A site Paromomycin Neomycin 37
40-O-ether
1
40,60-O-acetal
39
40-O-ether
2
40,60-O-acetal
42
40-O-ether
30
40,60-O-acetal
Wild type 0.03 0.03 0.14 0.28 0.14 0.14 0.28 0.14
G1491C 19.2 1.1 122.0 131.0 83.3 80.4 255.5 163.5
G1491A 1.1 0.08 38.4 79.3 29.0 43.0 87.4 66.4
A1408G 0.5 31.4 17.5 19.0 5.9 10.5 16.1 9.5
Table 1 | Minimal inhibitory concentrations (MIC, lM) of 40,60-O-benzylidene acetals.
Bacterial A site 
Neomycin 
Ring I 
Paromomycin 
Ring I 1 2 3 9 30 
WT 0.8 1.6 5.6 5.6 5.6 2.8–5.6 2.8  
1491C 27 >720 >720 >720 >720 720 ≥720 
1491A 3.2 51-102 720 >720 >720 720 ≥720 
1408G >720 51-102 720 >720 >720 >720 720  
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available 4,5 and 4,6 2-deoxystreptamines and as per interaction
with the eukaryotic ribosome the present series of compounds
have retained aminoglycoside selectivity for the cytosolic ribo-
some, but show decreased interaction with mitochondrial wild
type and, in particular, mitochondrial mutant deafness hybrid
ribosomes (Fig. 2).
Aminoglycoside-mediated dysfunction of the eukaryotic ribo-
some has been connected to drug cytotoxicity in mammalian
cells9,18,23,24. To assess the potential cytotoxicity of the 40,60-O-
acetals and the 40-O-ethers we determined cell toxicity of
compounds 1, 30, 37 and 39 in HEK293 cells. Cytotoxicity of
the compounds was signiﬁcantly lower than that of geneticin, an
aminoglycoside known to be cytotoxic to mammalian cells (see
Supplementary Fig. 4).
Determination of antibacterial activity. To assess antimicrobial
activity, we determined the MIC values of compounds 1, 2, 30,
37, 39 and 42 against clinical isolates of Escherichia coli
and Staphylococcus aureus in comparison to those of
paromomycin and aminoglycosides used in the clinic for the
treatment of infectious diseases, that is, gentamicin, tobramycin,
kanamycin and amikacin (Table 5). The acetals and ethers—in
particular the arylalkyl ethers 39 and 42—showed antimicrobial
activity that was comparable to that of the parental
paromomycin.
To investigate whether the in vitro activity of our compounds
translates to activity in vivo, we determined the antibacterial
in vivo activity in neutropenic murine models of septicaemia25,26.
Efﬁcacy of compounds 30, 37 and 39 was compared with
amikacin and the parental paromomycin. In animals infected
with methicillin-resistant S. aureus, treatment with 30, 37 and 39
reduced the bacterial burden both in blood and in kidney and was
as effective as the comparator amikacin and the parental
paromomycin. Compared with the vehicle-treated mice, drug
treatment reduced bacterial burden in the kidney between 3 to 6
log10 and in blood between 2 to 3 log10 in a dose-dependent
manner. Among all drugs studied, the greatest efﬁcacy in
reducing S. aureus burden in the blood was following treatment
with 30 and 37, which both reduced the bacterial burden below
detectable limits (Fig. 3).
Crystal structure analysis. The distinct ribosomal activity proﬁle
of the acetal and ether derivatives differentiates them from
available 4,5- and 4,6-disubstituted aminoglycosides. To study the
structural basis of drug-target interaction we determined the
three-dimensional (3D) structure of a number of the acetals and
ethers in complex with the small ribosomal subunit of Thermus
thermophilus. Two acetals, the parental phenyl derivative 1 and
the most active phenethyl analogue 30, and two ethers, the 40-O-
benzyl ether 37 and the closely related 4-(chlorophenyl) methyl
ether 39 were chosen for analysis.
The overall structures of the 30S subunit in complex with all
four compounds were globally similar to previous 30S ribosomal
subunit structures (with RNA phosphate root mean-squared
deviation of B0.6 Å). Both acetals (1, 30) and ethers (37, 39)
were found inserted in the major groove of helix 44 of 16S rRNA
in a manner that resembles the structures of 30S–apramycin27
and 30S–paromomycin10 complexes (Fig. 4 and Supplementary
Figs 5 and 6). Similar to paromomycin, rings II, III and IV of all
four derivatives maintained their interactions with residues in
helix 44, showing that neither the acetal nor the ether
Table 4 | Compound interaction with hybrid ribosomes—selectivity proﬁle (IC50, lM).
Eukaryotic A site Paromomycin Neomycin 37
40-O-ether
1
40,60-O-acetal
39
40-O-ether
2
40,60-O-acetal
42
40-O-ether
30
40,60-O-acetal
Mitochondrial wild type 81.5 2.9 93.7 127.5 120.7 115.1 85.0 259.7
Mitochondrial mutant A1555G 6.7 0.3 67.9 61.3 71.5 65.8 118.6 161.8
Mitochondrial mutant C1494U 5.1 0.3 69.3 53.3 53.3 51.1 121.2 168.7
Cytosolic wild type 14.4 29.4 87.8 66.8 94.1 93.7 225.1 203.7
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Figure 2 | Drug-induced inhibition of protein synthesis in ribosomes.
Inhibition of protein synthesis depicted as IC50 (mM); IC50 values represent
the drug concentrations required to inhibit in vitro synthesis of ﬁreﬂy
luciferase to 50%. (a) y axis: IC50 mitohybrid ribosomes, x axis: IC50 rabbit
reticulocyte ribosomes; (b) y axis: IC50 mitohybrid deafness ribosomes,
x axis: IC50 rabbit reticulocyte ribosomes.
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modiﬁcations alter the fundamental binding mode to the
ribosome. However, the orientations of A1492 and A1493 that
are extruded from helix 44 were tilted relative to the
paromomycin structure (Fig. 4c,d). The synthetically added
substituents of compounds 1 and 30, which result in a ring
system mimicking apramycin’s bicyclic moiety, stacked perfectly
with the nucleobase of G1491. Unlike all other aminoglycosides
that form a pseudo basepair interaction between ring I and A1408
consisting of two hydrogen bonds, no pseudobase interaction was
observed for the acetal series as a consequence of the absence of
hydrogen bonding with N1 of A1408. The loss of this interaction
constitutes the main structural difference between the benzyli-
dene and benzyl compounds examined (37, 39). For both the
benzyl and benzylidene compounds (1, 30, 37 and 39), the
40-O-substituent prevents hydrogen bonding with O2P of A1493
(Fig. 4e). The aromatic substituent is positioned in the minor
groove of the 1409–1491 basepair in proximity to the backbone
and ribose of A1492. It mainly points out into the solvent and
does not show stacking interaction to ribosomal moieties.
The 3D structure of the drug–ribosome interaction and the
benzylidene acetal’s chemical structure resemble that of apramy-
cin, while the IC50 values for mutant ribosomes indicate
important differences. Compared with the 40,60-O-acetals and
their susceptibility to mutational alteration of residue 1491, the
antiribosomal activity (IC50) of apramycin is strongly affected by
the A1408G alteration (see Supplementary Table 2 and compare
to Table 3). To challenge these disparate ﬁndings we synthesized
44 by removing rings 3 and 4 from the 40,60-O-benzylidene acetal
1 (for a comparison of the structure of 44 and apramycin both
isolated and in complex with the ribosome, see Supplementary
Fig. 7). In contrast to apramycin, compound 44 had virtually no
activity on any of the bacterial ribosomes tested (Supplementary
Table 2). Further evidence for a distinct mode of interaction of
the 40,60-O-benzylidene acetals with the ribosome as compared
with apramycin was found in their ability to induce misreading.
The effects were studied on bacterial ribosomes and on eukaryotic
cytosolic ribosomes, using acetal 1 as representative in compar-
ison to apramycin and paromomycin. Acetal 1 induced
pronounced misreading on bacterial ribosomes but little if any
misreading on eukaryotic ribosomes (Fig. 5). This unique pattern
of misreading induction differentiates acetal 1 from both the
parental paromomycin (misreading on both bacterial and
eukaryotic ribosomes) and the comparator apramycin (no
misreading on bacterial or eukaryotic ribosomes).
Discussion
Here we addressed the question of whether it is possible to
modify 4,5-disubstituted 2-deoxystreptamine aminoglycosides
that show a preference for either the cytoplasmic ribosome
(paromomycin) or the mitochondrial ribosome (neomycin), but
which have comparable activities for the bacterial ribosome. With
a view to develop aminoglycoside derivatives that are more
selective at the ribosomal target level, chemical synthesis was
guided by a collection of mutant bacterial ribosomes with single
point mutations in h44. Previous work has established the
important role of this mutant model system in understanding the
SAR of aminoglycosides and mechanisms of antibiotic action20,21.
A selective response of aminoglycosides to alterations of rRNA
residues 1408 or 1491 (E. coli numbering) can potentially
overcome drug ototoxicity8,9,17,27.
We succeeded in the synthesis of a series of compounds that
exploit the polymorphic residues present in the drug-binding
pocket. Phylogenetic selectivity in aminoglycoside binding
involves rRNA residue 1491C for mitoribosomes and rRNA
residues 1491A and 1408G for cytoribosomes9,17,18. Compared
with the parental scaffolds paromomycin and neomycin the 40,60-
O-acetals and 40-O-ethers are highly susceptible to any alteration
of residues 1408 or 1491 (Table 3). Hybrid ribosomes carrying the
cytoplasmic A site, the mitochondrial wild-type A site or the
mitochondrial deafness A site (A1555G, C1494U) were used to
study compound interaction with the eukaryotic drug-binding
pockets. These bacterial hybrid ribosomes have been
shown to faithfully reﬂect drug susceptibility of eukaryotic
ribosomes8,9,18,27. In contrast to paromomycin or neomycin,
the series of 40,60-O-acetals and 40-O-ethers have lost most, if not
all of the preferential activity for any of the eukaryotic drug-
binding pockets—these compounds bind poorly to mitochondrial
wild-type and cytosolic hybrid ribosomes (Table 4) and have also
lost the aminoglycosides’ characteristic activity for the mito-
chondrial mutant deafness A site9. However, these compounds
retain to a large extent their activity for bacterial ribosomes and
show good antibacterial activity in vitro and in vivo (Table 5,
Fig. 3). These results identify C(40) and its substituents as
promising sites through which the drug–target interaction can be
manipulated for increased selectivity.
By crystal structure analysis an additional aminoglycoside-
binding site at helix 69 of the 23S rRNA has been postulated in
bacterial ribosomes28,29. Although single-molecule measurements
point to an involvement of H69 in aminoglycoside-mediated
inhibition of translocation and ribosome recycling30, the
implications of this suggested additional binding site for
aminoglycoside action are as yet unclear, as mutations in H69
reportedly have not been associated with aminoglycoside
resistance. In contrast, single point mutations in the A site at
16S rRNA positions 1408 and 1491 are both necessary and
sufﬁcient to confer non-responsiveness to aminoglycoside action
in bacteria16,20,21.
Table 5 | Minimal inhibitory concentrations (MIC, lM) of clinical isolates.
Gentamicin Tobramycin Kanamycin Amikacin Paromomycin 37
40-O-ether
1
40,60-O-acetal
39
40-O-ether
2
40,60-O-acetal
42
40-O-ether
30
40,60-O-acetal
Staphylococcus aureus (MRSA)
AG 042 70–140 Z538 538 27 4415 22 22 5.6–11 5.6–11 5.6 5.6–11
AG 043 70–140 67 269–538 14–27 6.5–13 11–22 11–22 5.6 11 5.6–11 5.6
AG 044 35 17 134 6.8 6.5–13 22 22–45 11–22 22 11 22
AG 045 35 17 134 6.8 6.5 22 22–45 11 11–22 5.6–11 22
AG 053 70–140 34–67 538 14 6.5 11 22 5.6 11 5.6–11 5.6–11
Escherichia coli
AG 001 8.8–18 8.4–17 34 n.d. 26–52 45–90 45–90 11–22 22–45 22 45–90
AG 002 4.4 4.2 8.4–17 n.d. 13–26 45–90 45–90 22 22–45 22 45–90
AG 003 560–1120 67 34–67 n.d. 13–26 45–90 45 11–22 22–45 11–22 45
AG 004 1120 134 67–134 n.d. 52 45–90 90 11–22 22–45 22 22–45
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The molecular basis for the compounds’ increased selectivity
was revealed by the observation that it is possible to separate
compound interaction with residue 1408 (main denominator of
cytosolic selectivity) from compound interaction with residue
1491 (main denominator of mitochondrial selectivity), that is,
aminoglycoside activity for A1408G mutant ribosomes does not
go hand-in-hand with activity for G1491C mutant ribosomes.
This separation of ribosomal activities has provided the basis
for the synthesis of more selective aminoglycosides, that is,
compounds with a selective decrease in activity for mito-
ribosomes (mitochondrial wild type, mitochondrial mutant
deafness) but not at the expense of increased activity for the
cytoribosome (Fig. 2).
The structural basis for the altered speciﬁcity of the series of
modiﬁed aminoglycosides is unclear. Globally, the crystal
structures of the bacterial 30S subunit in complex
with compounds 1, 30, 37 and 39 resemble the structures of
available 30S–aminoglycoside complexes10,11, in particular the
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Figure 3 | In vivo activity of aminoglycoside compounds and comparators in a murine septicaemia model. (a) Bacterial burden in kidney, CFU per g
tissue. (b) Bacterial burden in blood, CFUml 1. The CFU values for the individual animals are indicated by dots, the mean of the group (ﬁve mice
per treatment group) by the bar. The log reduction compared with the vehicle control as well as the P-values (non-parametric Kruskal–Wallis using pairwise
comparisons) are indicated as numbers above each group. Colour coding—pre-treatment: light grey; vehicle control: dark grey; 30: red; 39: orange;
37: green; amikacin: light blue; paromomycin: dark blue; linezolid: violet. LOD, limit of detection.
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30S–apramycin complex27, even if subtle differences are present
(see Results and Fig. 4). This work exempliﬁes the difﬁculty of
predicting speciﬁcity at the typical resolutions of B3Å as for
current ribosomal crystal structures. Such speciﬁcity may arise as
the result of subtle energetics that cannot easily be deduced
from the structures. A more thorough understanding of the
structural basis for the compounds’ selectivity will require a
careful comparison with structures of both higher eukaryotic
cytosolic and mitochondrial ribosomes in complex with
2-deoxystreptamine aminoglycosides, preferably at higher
resolutions than possible to date. Such structures are currently
not feasible because the appropriate experimental conditions have
not been established. At the functional level, misreading-inducing
activity on bacterial ribosomes but not on eukaryotic ribosomes
(Fig. 5) and the compounds’ unique structure–activity proﬁles of
drug–mutant ribosome interaction (Table 3) differentiates them
from available aminoglycosides, and establishes the series of 40
modiﬁcations as a novel chemotype with a unique mode of
interaction with h44.
Interest in aminoglycosides has recently seen a revival not least
because structural details of drug–target interactions and
aminoglycoside-modifying enzymes have provided a wealth of
knowledge31–33, facilitating hypothesis-driven approaches to
developing aminoglycosides recalcitrant to resistance
determinants34–36. The description of aminoglycoside–ribosome
complexes at atomic resolution10,11 has greatly stimulated efforts
at structure-based design of new bioactive derivatives37–42.
However, rational design of speciﬁcity using these structures is
limited by the current resolution of crystallographic analysis and
an incomplete understanding of the thermodynamic and kinetic
factors involved in antibiotic binding43,44. These limitations
in understanding small molecule–RNA interactions and the
constraints imposed by the limited sequence polymorphism in
the drug-binding pocket make it a formidable challenge to
Compound 1
Compound 1
Compound 1
Paromomycin
Paromomycin
A1493
IV
IV
III
II
I
O2P
O4’
1 30 37 39
III
II
I
A1493A1492
A1492
A1493
A1492
S12
Helix 44 (16S)
Figure 4 | Structures of antibiotics bound to the decoding center of the 30S ribosomal subunit. (a) 3Fo—2Fc difference Fourier density around compound
1 (green) contoured at 1.0s. (b) Superposition of antibiotics in the decoding center, colour coding as indicated by the numbering. (c) Decoding center
of the 30S subunit (helix 44 of 16S RNA, orange; protein S12, light green), showing compound 1 in green. The conformation of A1492 and A1493 (grey) is
shown. The benzyl ring is in proximity to the nucleobase of the ﬂipped-out A1492. Also shown is a superposition with paromomycin (Par, salmon).
(d) Superposition of helix 44 of 16S RNA for structures of 30S-compound 1 (green) and 30S-paromomycin (salmon, Protein Data Bank ID code 1FJG); the
orientations of A1492 and A1493 that are ﬂipped-out from helix 44 are tilted relative to the paromomycin structure. (e) View of compound 1 and loss of a
hydrogen bond with O2P of A1493 compared with paromomycin. The benzyl ring is in proximity to the nucleobase of the ﬂipped-out A1492.
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synthesize aminoglycosides that are more selective at the drug-
target level. The combined chemical synthesis, structural analysis,
genetics and functional studies employed here have enabled
us to manipulate a complex biological system of drug–target
interaction. By introducing deﬁned substitutions we have
identiﬁed a new chemotype of aminoglycosides with increased
selectivity and little activity for any of the human drug-binding
pockets, an important step towards the development of less toxic
aminoglycosides.
Methods
Antibiotics. Paromomycin, neomycin, gentamicin, tobramycin, kanamycin, ami-
kacin and apramycin were obtained from Sigma.
Compound synthesis. Chemical synthesis procedures are detailed in the
Supplementary Methods.
Strains harbouring mutant ribosomes. The construction of these strains, which
are derived from single rRNA allelic M. smegmatis DrrnB, has been described
previously8,18. They consist of recombinant mutant strains with single point
mutations in the small ribosomal subunit A site (16S rRNA positions 1408A-G,
1491G-A and 1491G-C) and mutant strains with hybrid ribosomes where the
bacterial A site had been replaced by various eukaryotic homologues
(cytoribosome, mitoribosome and deafness mitoribosome).
Bacterial strains. Clinical isolates of E. coli and S. aureus were obtained from the
Diagnostic Department, Institute of Medical Microbiology, University Zurich. MIC
values were determined by broth microdilution assays. Microtitre plates were
incubated overnight for E. coli and S. aureus, and 72 h for M. smegmatis.
In vivo infection experiments. All animal experiments were performed under UK
Home Ofﬁce Licenses with clearance by the ethical review committee at the
University of Manchester. Male mice aged 7–8 weeks were used in this study. Mice
were supplied by Charles River UK and were speciﬁc pathogen-free. The strain of
mouse used was Hsd:ICR (CD-1), which is a well-characterized outbred strain.
Mice weights at the start of the experiment were 22–25 g. Mice were housed in
sterile individual ventilated cages with free access to sterile food and water and
were exposed to 12 h light/dark cycles with dawn/dusk phases. Five mice were used
in each group.
Mice were rendered temporarily neutropenic by immunosuppression with
cyclophosphamide at 200mg kg 1 4 days before infection and 150mg kg 1 1 day
before infection by intraperitoneal injection. The immunosuppression regime leads
to neutropenia starting 24 h post administration, which continues throughout the
study. For in vivo infection a methicillin-resistant strain of Staphylococcus aureus,
clinical isolate MRSA AG041, was used. Twenty four hours post the second round
of immunosuppression mice were infected with S. aureus MRSA AG041 by
intravenous injection into the lateral tail vein usingB1 107 CFU per mouse. This
strain had the following MIC values (mM given in brackets)—amikacin 4.0mg l 1
(7.0), paromomycin 4.0mg l 1 (6.5), 30 4.0mg l 1 (5.6), 37 8.0mg l 1 (11.2), 39
4.0mg l 1 (5.6) and linezolid 1.0mg l 1. Compounds 30, 37, 39 and comparator
amikacin were administered at 4 times and at 10 times the MIC value in mg kg 1,
the parental paromomycin at four times the MIC value in mg kg 1. Linezolid
(20mg kg 1) was used as positive control. Test articles and comparators were
reconstituted and diluted in 0.9% saline. Dosing solutions were prepared
immediately prior to administration of the ﬁrst dose and stored at 4 C between
treatments. Antibacterial treatment was initiated 1 h post infection and delivered
subcutaneously at 10ml kg 1 (linezolid was given by intravenous bolus injection).
All drugs were administered at 1, 9 and 17 h post infection.
At 1 h (pre-treatment group) or 24 h post infection blood samples were
collected by cardiac puncture under isoﬂurane anaesthesia and mice were
humanely killed using pentobarbitone overdose. Both kidneys were removed and
homogenized in 2ml ice cold sterile phosphate-buffered saline. Kidney
homogenates were quantitatively cultured onto mannitol salt agar (MSA) and
incubated at 37 C for 24 h before being counted. Individual blood samples were
quantitatively cultured onto cysteine lactose electrolyte-deﬁcient (CLED) agar and
incubated at 37 C for 24 h before being counted. Data were analysed, by
StatsDirect software (version 2.7.8), using the non-parametric Kruskal–Wallis test
(pairwise comparisons, Conover–Inman).
Isolation and puriﬁcation of ribosomes. Ribosomes were puriﬁed from bacterial
cell pellets as described previously45. In brief, ribosome particles were isolated by
successive centrifugation and fractionated by sucrose gradient (10–40%)
centrifugation. The 70S ribosome-enriched fraction was pelleted, resuspended in
association buffer, incubated for 30min at 4 C, dispensed into aliquots and stored
at  80 C following shock freezing in liquid nitrogen. Ribosome concentrations of
70S were determined by absorption measurements on the basis of 23 pmol
ribosomes per A260 unit. Integrity of puriﬁed 70S ribosomes was determined by
analytical ultracentrifugation.
Cell-free luciferase translation assays. Puriﬁed 70S hybrid ribosomes were used
in translation reactions of luciferase mRNA. Luciferase mRNA was produced
in vitro using T7 RNA polymerase (Thermo Scientiﬁc) on templates of modiﬁed
plasmids pGL4.14 (ﬁreﬂy luciferase) and pGL4.75 (renilla luciferase, both Pro-
mega), where the mammalian promoter driving transcription of luciferases was
replaced by the T7 bacteriophage promoter. A typical translation reaction with a
total volume of 30ml contained 0.25mM 70S ribosomes, 4 mg ﬁreﬂy (F-luc) mRNA,
0.4 mg renilla (R-luc) mRNA, 40% (vol/vol) M. smegmatis S100 extract, 200mM
amino acid mixture, 24 units of RiboLock (Thermo Scientiﬁc), 0.4mgml 1
tRNAs, and energy was supplied by addition of 12 ml of commercial S30 Premix
without amino acids (Promega). In addition to ribosomes, rabbit reticulocyte lysate
(Promega) was used for in vitro translation of F-luc mRNA. A standard 30 ml
reaction contained 20 ml reticulocyte lysate, 4 mg F-luc mRNA, 0.4 mg R-luc mRNA,
amino-acid mixture (200 mM each) and 24 units RiboLock. Following addition of
serially diluted aminoglycosides, the reaction mixture was incubated at 37 C for
35min and stopped on ice. Thirty microliter samples of the reaction mixture were
assayed for luciferase activities using the Dual Luciferase Reporter Assay System
(Promega). Luminescence was measured using a luminometer FLx800 (Bio-Tek
Instruments).
Misreading was assessed in a gain–of-function assay as described previously27.
In brief, we introduced Arg245 (CGC, near-cognate codon) into the ﬁreﬂy
luciferase protein to replace residue His245 (CAC codon). Arg245 F-luc mRNA
and wt F-luc mRNA were used in in vitro translation reactions; in addition, R-luc
mRNA was used as internal control. We quantiﬁed misreading by calculating
mutant ﬁreﬂy/renilla luciferase activity as compared with wild-type ﬁreﬂy/renilla
luciferase activity.
Crystal structure analysis. Crystals obtained from puriﬁed T. thermophilus 30S
ribosomes46 were soaked for 4 days in cryoprotectant solution (100mM MES-
KOH (pH 6.5), 200mM KCl, 75mM NH4Cl, 15mMMgCl2, 26% MPD and 100mM
antibiotic) before being ﬂash-frozen. Crystals were pre-screened and data sets were
collected at the European Synchrotron Radiation Facility (ESRF). Data were
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integrated and scaled using XDS47. A starting model consisting of the empty 30S
ribosome (without anticodon-stem loop, mRNA and ions) was used for initial
reﬁnement and phase calculation using CNS48. The anticodon-stem loop and
mRNA were then ﬁtted into the unbiased difference map (mFo–DFc map) and the
model was subjected to another round of reﬁnement. Finally, ligands were placed
manually into unbiased difference maps (mFo–DFc map) using COOT49, which
were reﬁned to resolutions between 2.9 and 3.5 Å. Data and reﬁnement statistics
are reported in Supplementary Table 3.
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